Cargando…

Systemic and local evidence for complement involvement in chronic spontaneous urticaria

BACKGROUND: The pathogenesis of chronic spontaneous urticaria (CSU), including the mechanism of action of omalizumab, remain unclear. We hypothesized complement system involvement given the often fast clinical response induced by treatment, including omalizumab. Therefore, we assessed the role of va...

Descripción completa

Detalles Bibliográficos
Autores principales: Alizadeh Aghdam, Mehran, van den Elzen, Mignon, van Os‐Medendorp, Harmieke, van Dijk, Marijke R., Knol, Edward F., Knulst, André C., Röckmann, Heike, Otten, Henny G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254579/
https://www.ncbi.nlm.nih.gov/pubmed/34262691
http://dx.doi.org/10.1002/clt2.12011
_version_ 1783717757190144000
author Alizadeh Aghdam, Mehran
van den Elzen, Mignon
van Os‐Medendorp, Harmieke
van Dijk, Marijke R.
Knol, Edward F.
Knulst, André C.
Röckmann, Heike
Otten, Henny G.
author_facet Alizadeh Aghdam, Mehran
van den Elzen, Mignon
van Os‐Medendorp, Harmieke
van Dijk, Marijke R.
Knol, Edward F.
Knulst, André C.
Röckmann, Heike
Otten, Henny G.
author_sort Alizadeh Aghdam, Mehran
collection PubMed
description BACKGROUND: The pathogenesis of chronic spontaneous urticaria (CSU), including the mechanism of action of omalizumab, remain unclear. We hypothesized complement system involvement given the often fast clinical response induced by treatment, including omalizumab. Therefore, we assessed the role of various complement factors surrounding omalizumab treatment. METHODS: Thirty CSU patients (median age 42 [range 21–70]; 73 % female) with a median once daily Urticaria Activity Score over 7 days (UAS7) score at baseline of 31.5 points were enrolled. Treatment consisted of six administrations of 300 mg omalizumab every 4 weeks succeeded by a follow‐up period of 12 weeks. Four punch skin biopsies were taken per patient; at baseline from lesional skin, at baseline from nonlesional skin, and after 1 and 7 days from formerly lesional skin. Complement activity, including C1q, C3, C3bc/C3, C4, C4bc/C4, C5a, and Membrane Attack Complex in peripheral blood were analyzed and complement activation in the skin was determined by the analysis of C4d deposition. Results were related to the clinical response to omalizumab. RESULTS: Fifteen patients showed a UAS7 score of 6 or lower (median 0) at Week 24, 15 patients did not (median 16). Lesional skin biopsies at baseline revealed complement deposition (C4d) in blood vessels in the papillary dermis of 53% (16/30) of the patients, which suggests involvement of immune complexes in the pathogenesis of urticaria. Moreover, indication of increased complement activation in CSU was substantiated by increased C5a levels in peripheral blood compared to healthy controls (p = 0.010). The clinical effect of omalizumab could not be linked to the variation of complement components. CONCLUSIONS: Both C4d deposition in lesional skin and elevated C5a levels in peripheral blood indicate the involvement of complement activation in the pathogenesis of CSU. No correlation was found between omalizumab and activation of complement indicative of independent processes in the immunopathogenesis of CSU.
format Online
Article
Text
id pubmed-8254579
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-82545792021-07-13 Systemic and local evidence for complement involvement in chronic spontaneous urticaria Alizadeh Aghdam, Mehran van den Elzen, Mignon van Os‐Medendorp, Harmieke van Dijk, Marijke R. Knol, Edward F. Knulst, André C. Röckmann, Heike Otten, Henny G. Clin Transl Allergy Research BACKGROUND: The pathogenesis of chronic spontaneous urticaria (CSU), including the mechanism of action of omalizumab, remain unclear. We hypothesized complement system involvement given the often fast clinical response induced by treatment, including omalizumab. Therefore, we assessed the role of various complement factors surrounding omalizumab treatment. METHODS: Thirty CSU patients (median age 42 [range 21–70]; 73 % female) with a median once daily Urticaria Activity Score over 7 days (UAS7) score at baseline of 31.5 points were enrolled. Treatment consisted of six administrations of 300 mg omalizumab every 4 weeks succeeded by a follow‐up period of 12 weeks. Four punch skin biopsies were taken per patient; at baseline from lesional skin, at baseline from nonlesional skin, and after 1 and 7 days from formerly lesional skin. Complement activity, including C1q, C3, C3bc/C3, C4, C4bc/C4, C5a, and Membrane Attack Complex in peripheral blood were analyzed and complement activation in the skin was determined by the analysis of C4d deposition. Results were related to the clinical response to omalizumab. RESULTS: Fifteen patients showed a UAS7 score of 6 or lower (median 0) at Week 24, 15 patients did not (median 16). Lesional skin biopsies at baseline revealed complement deposition (C4d) in blood vessels in the papillary dermis of 53% (16/30) of the patients, which suggests involvement of immune complexes in the pathogenesis of urticaria. Moreover, indication of increased complement activation in CSU was substantiated by increased C5a levels in peripheral blood compared to healthy controls (p = 0.010). The clinical effect of omalizumab could not be linked to the variation of complement components. CONCLUSIONS: Both C4d deposition in lesional skin and elevated C5a levels in peripheral blood indicate the involvement of complement activation in the pathogenesis of CSU. No correlation was found between omalizumab and activation of complement indicative of independent processes in the immunopathogenesis of CSU. John Wiley and Sons Inc. 2021-07-03 /pmc/articles/PMC8254579/ /pubmed/34262691 http://dx.doi.org/10.1002/clt2.12011 Text en © 2021 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Alizadeh Aghdam, Mehran
van den Elzen, Mignon
van Os‐Medendorp, Harmieke
van Dijk, Marijke R.
Knol, Edward F.
Knulst, André C.
Röckmann, Heike
Otten, Henny G.
Systemic and local evidence for complement involvement in chronic spontaneous urticaria
title Systemic and local evidence for complement involvement in chronic spontaneous urticaria
title_full Systemic and local evidence for complement involvement in chronic spontaneous urticaria
title_fullStr Systemic and local evidence for complement involvement in chronic spontaneous urticaria
title_full_unstemmed Systemic and local evidence for complement involvement in chronic spontaneous urticaria
title_short Systemic and local evidence for complement involvement in chronic spontaneous urticaria
title_sort systemic and local evidence for complement involvement in chronic spontaneous urticaria
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254579/
https://www.ncbi.nlm.nih.gov/pubmed/34262691
http://dx.doi.org/10.1002/clt2.12011
work_keys_str_mv AT alizadehaghdammehran systemicandlocalevidenceforcomplementinvolvementinchronicspontaneousurticaria
AT vandenelzenmignon systemicandlocalevidenceforcomplementinvolvementinchronicspontaneousurticaria
AT vanosmedendorpharmieke systemicandlocalevidenceforcomplementinvolvementinchronicspontaneousurticaria
AT vandijkmarijker systemicandlocalevidenceforcomplementinvolvementinchronicspontaneousurticaria
AT knoledwardf systemicandlocalevidenceforcomplementinvolvementinchronicspontaneousurticaria
AT knulstandrec systemicandlocalevidenceforcomplementinvolvementinchronicspontaneousurticaria
AT rockmannheike systemicandlocalevidenceforcomplementinvolvementinchronicspontaneousurticaria
AT ottenhennyg systemicandlocalevidenceforcomplementinvolvementinchronicspontaneousurticaria